The Floodgates are set to open.
Today we learned that Dexcom was among the investors in a Series B funding round for diabetes/obesity startup Signos. The Friday before Ilant Health a “new virtual provider targeting obesity treatment” launched with $3 million in funding. I’m pretty sure there are more that we missed but this is just the beginning. Get ready for investor money to start pouring into what we are calling the Ozempic Cost Containment (OCC) space.
Although this is not directly related to OCC also look for all the patient advocates to start calling for a reduction in the cost of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.